Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Werewolf Therapeutics (HOWL) Equity Ratio (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Equity Ratio for 5 consecutive years, with 0.37 as the latest value for Q3 2025.

  • On a quarterly basis, Equity Ratio fell 41.73% to 0.37 in Q3 2025 year-over-year; TTM through Sep 2025 was 0.37, a 41.73% decrease, with the full-year FY2024 number at 0.58, down 9.24% from a year prior.
  • Equity Ratio was 0.37 for Q3 2025 at Werewolf Therapeutics, down from 0.45 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.95 in Q2 2021 to a low of 1.72 in Q1 2021.
  • A 5-year average of 0.56 and a median of 0.64 in 2023 define the central range for Equity Ratio.
  • Peak YoY movement for Equity Ratio: surged 149.22% in 2022, then tumbled 41.73% in 2025.
  • Werewolf Therapeutics' Equity Ratio stood at 0.85 in 2021, then fell by 10.43% to 0.76 in 2022, then dropped by 16.56% to 0.64 in 2023, then dropped by 9.24% to 0.58 in 2024, then tumbled by 35.68% to 0.37 in 2025.
  • Per Business Quant, the three most recent readings for HOWL's Equity Ratio are 0.37 (Q3 2025), 0.45 (Q2 2025), and 0.53 (Q1 2025).